Neuropeptide y stimulates proliferation and migration in the 4T1 breast cancer cell line

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 276-286

  Medeiros, Philip J ^a   Al Khazraji, Baraa K ^a   Novielli, Nicole M ^a   Postovit, Lynne M ^b   Chambers, Ann F ^a,b,c   Jackson, Dwayne N ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

4T1 mammary carcinoma; breast cancer; chemotaxis; Neuropeptide Y; Y1 receptor; Y2 receptor; Y5 receptor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROPEPTIDE Y; PHOSPHORYLATION; RECEPTORS, NEUROPEPTIDE Y; SIGNAL TRANSDUCTION;

EID: 84861589886     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26350     Document Type: Article

References (33)

1. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK,. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006; 6: 240-8.
2. Tilan J, Kitlinska J, Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol 2010; 2010: 539706.
3. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES,. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
4. Marsland AL, Bachen EA, Cohen S, Rabin B, Manuck SB,. Stress, immune reactivity and susceptibility to infectious disease. Physiol Behav 2002; 77: 711-16.
5. McEwen BS, Stellar E,. Stress and the individual. Mechanisms leading to disease. Arch Intern Med 1993; 153: 2093-101.
6. James GD, Berge-Landry Hv H, Valdimarsdottir HB, Montgomery GH, Bovbjerg DH,. Urinary catecholamine levels in daily life are elevated in women at familial risk of breast cancer. Psychoneuroendocrinology 2004; 29: 831-8.
7. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T,. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50: 143-50.
8. Ruscica M, Dozio E, Motta M, Magni P,. Relevance of the neuropeptide Y system in the biology of cancer progression. Curr Top Med Chem 2007; 7: 1682-91.
9. Kuo LE, Abe K, Zukowska Z,. Stress, NPY and vascular remodeling: implications for stress-related diseases. Peptides 2007; 28: 435-40.
10. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS,. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83: 187-95.
11. Zukowska-Grojec Z, Pruszczyk P, Colton C, Yao J, Shen GH, Myers AK, Wahlestedt C,. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 1993; 14: 263-8.
12. Reubi JC, Gugger M, Waser B, Schaer JC,. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001; 61: 4636-41.
13. Sheriff S, Ali M, Yahya A, Haider KH, Balasubramaniam A, Amlal H,. Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Mol Cancer Res 2010; 8: 604-14.
14. Amlal H, Faroqui S, Balasubramaniam A, Sheriff S,. Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. Cancer Res 2006; 66: 3706-14.
15. Korner M, Reubi JC,. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors. J Neuropathol Exp Neurol 2008; 67: 741-9.
16. Kitlinska J, Abe K, Kuo L, Pons J, Yu M, Li L, Tilan J, Everhart L, Lee EW, Zukowska Z, Toretsky JA,. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005; 65: 1719-28.
17. Straub RH, Mayer M, Kreutz M, Leeb S, Scholmerich J, Falk W,. Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. J Leukoc Biol 2000; 67: 553-8.
18. Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z,. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 2006; 20: 1924-6.
19. Drell TLt, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F,. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80: 63-70.
20. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG,. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95: 8829-34.
21. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ,. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18.
22. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
23. Magni P, Motta M,. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 2001; 12 (Suppl 2): S27-S29.
24. Korner M, Waser B, Reubi JC,. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 2004; 84: 71-80.
25. Ruscica M, Dozio E, Boghossian S, Bovo G, Martos Riano V, Motta M, Magni P,. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 2006; 147: 1466-73.
26. Kitlinska J,. Neuropeptide Y in neural crest-derived tumors: effect on growth and vascularization. Cancer Lett 2007; 245: 293-302.
27. Kitlinska J,. Neuropeptide Y (NPY) in neuroblastoma: effect on growth and vascularization. Peptides 2007; 28: 405-12.
28. Pellieux C, Sauthier T, Domenighetti A, Marsh DJ, Palmiter RD, Brunner HR, Pedrazzini T,. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci USA 2000; 97: 1595-600.
29. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H,. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 1998; 75-76: 231-8.
30. Bibby MC,. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004; 40: 852-7.
31. Eccles SA, Box G, Court W, Sandle J, Dean CJ,. Preclinical models for the evaluation of targeted therapies of metastatic disease. Cell Biophys 1994; 24-25: 279-91.
32. Pulaski BA, Ostrand-Rosenberg S,. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486-93.
33. Pulaski BA, Ostrand-Rosenberg S,. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; Chapter 20: Unit 20.2.